Reported Earlier, Amylyx Pharmaceuticals Prices Upsized $500M Public Offering Of 14,090,000 Common Shares At $35.50 Per Share

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Benzinga Bulls and Bears: Ross, Moderna, Webull

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.

8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)

Filed: 2026-08-20 AccNo: 0001193125-26-359418 Size: 411 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits